CLINICAL_TRIALS trial_result · 2024-06-24

Clinical Trial Update: Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma [Phase 1]

A Phase 1 trial evaluating BAL101553 in combination with radiation for newly diagnosed glioblastoma was terminated, with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Basilea Pharmaceutica | Conditions: Glioblastoma, MGMT-Unmethylated Glioblastoma | Phase 1 | Status: TERMINATED | Results posted: 2024-06-24